/
Neurology
Neurofibromatosis Type 1
8
Pipeline Programs↗
16
Active Trials↗
5
Companies Involved↗
Neurofibromatosis Type 1 is an early-stage landscape with 8 programs across 5 companies. The most active players are Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd., Shanghai Kechow Pharma, Inc..
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical2
Phase 1
No programs
Phase 26
Phase 3
No programs
Approved
No programs
Analysis
Trial Status
34
clinical trials
Completed14 · 41%
Active, not recruiting8 · 24%
Recruiting5 · 15%
Terminated3 · 9%
Not yet recruiting2 · 6%
Enrolling by invitation1 · 3%
Other1 · 3%
Clinical Trials
Trial Activity
34 trials
FCN-159 in Adult Patients With Symptomatic, Inoperable Neurofibromatosis Type 1-Related Plexiform Neurofibromas
Active, not recruiting·SShanghai Fosun Pharmaceutical Industrial Development Co. Ltd.·Phase 3·NCT05913037·167 enrolled
Antioxidant Therapy With N-acetylcysteine for Children With Neurofibromatosis Type 1
Active, not recruiting·—·Phase 2·NCT04481048·58 enrolled
Study to Evaluate the Safety, Tolerability, PK Characteristics and Anti-tumor Activity of FCN-159 in Adult and Pediatric Participants With Neurofibromatosis Type 1
Active, not recruiting·SShanghai Fosun Pharmaceutical Industrial Development Co. Ltd.·Phase 1/2·NCT04954001·160 enrolled
Follow-up Study to Evaluate the Safety and Efficacy of FCN-159 in Pediatric Participants With Neurofibromatosis Type 1
Not yet recruiting·SShanghai Fosun Pharmaceutical Industrial Development Co. Ltd.·Phase 1/2·NCT07024394·65 enrolled
Page 1 of 3
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)